Targeting Scap to Lower ApoB-Containing Lipoproteins (ApoBCL) Production
靶向 Scap 降低含 ApoB 脂蛋白 (ApoBCL) 的产生
基本信息
- 批准号:10543872
- 负责人:
- 金额:$ 54.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-01-01 至 2026-12-31
- 项目状态:未结题
- 来源:
- 关键词:Animal ExperimentsAnimal FeedAnimal ModelApolipoproteins BApplications GrantsBindingBinding ProteinsBinding SitesBloodCarbohydratesCell NucleusChemicalsCholesterolComplexCoronary ArteriosclerosisCoronary heart diseaseDevelopmentDietDissociationDrug KineticsEligibility DeterminationEndoplasmic ReticulumFatty AcidsGene ActivationGenesGoalsGolgi ApparatusHamstersHeart DiseasesHepaticHigh Fat DietLaboratoriesLeadLipidsLipoproteinsLiverMedicineMembraneMembrane ProteinsMetabolicModelingModificationMolecularMusNuclearPatientsPeptide HydrolasesPlasmaProcessProductionPropertyProteinsRapid screeningRegulatory ElementResearch Project GrantsResidual stateRiskRisk ReductionScienceSpecificityStabilizing AgentsSterolsStructureTranscriptional ActivationTriglyceridesWild Type Mousecardiovascular risk factorcholesterol-binding proteinimprovedin vivoindexinginhibitorlipid biosynthesislipid disordermimeticsnanomolarnovelnovel drug classnovel strategiesnovel therapeutic interventionnovel therapeuticspreventprotein complexsmall moleculesmall molecule inhibitorthree dimensional structuretranscription factor
项目摘要
Elevated plasma levels of triglyceride-rich ApoBCLs (ApoB-Containing Lipoproteins) constitute a major
component of the residual risk for coronary heart disease (CHD) in patients who have been treated with statins
and/or PCSK9 inhibitors. To mitigate the ApoBCL risk component, we need a deeper understanding of the
machinery that controls the production of ApoBCLs. This machinery is comprised of two membrane proteins,
Scap and Sterol Regulatory Element-Binding Proteins (SREBPs). Scap is a protein embedded in the
endoplasmic reticulum (ER) membrane through eight transmembrane helices. Scap forms complexes with
SREBPs, which are also bound to the ER membrane through two transmembrane helices. SREBPs contain
transcription factor domains that control the synthesis of fatty acids, triglycerides, and cholesterol, which form
the lipid component of ApoBCLs. Activation of SREBPs requires their transport by Scap to the Golgi where two
proteases release their transcription factor domain that can now enter the nucleus for target gene activation.
When cholesterol in the ER rises and binds to Scap, it traps SREBPs in the ER, thus preventing proteolytic
cleavage and nuclear entry. A major hurdle in understanding Scap’s switch-like molecular mechanism and how
it controls SREBPs and ApoBCL production is the lack of a soluble cholesterol-mimetic compound that
specifically binds and inhibits Scap.
This proposal is based on a recent breakthrough in our laboratory involving the development of a novel high-
throughput and rapid screening protocol, which has identified the first small molecule that binds specifically to
Scap’s cholesterol-binding site and blocks activation of SREBPs. Scap contains two large loops (Loop1 and
Loop7) that extend into the lumen of the ER bind each other when cholesterol in the ER is low. When ER
cholesterol rises, it binds to Loop1, causing Loop1 to dissociate from Loop7, trapping the Scap/SREBP complex
in the ER and blocking the transcriptional activation of all SREBP target genes. In Aim 1, we outline studies to
improve the potency of our recently discovered cholesterol-mimetic Scap inhibitor and will use these inhibitors
to understand how Loop1 dissociates from Loop7. The inhibitors will also be used as stabilizing agents to enable
structural determination of Scap, which will elucidate the cholesterol binding mechanism at an atomic level. In
Aim 2, we outline our approach to optimizing the in vivo pharmacokinetic properties of our various Scap
inhibitors, after which we will explore their effects in inhibiting Scap and SREBP target genes in livers of mice
under different metabolic conditions. Our previous studies involving genetically altered mice revealed that
inhibition of Scap in the liver blocks SREBPs and markedly reduces synthesis of fatty acids, triglycerides, and
cholesterol, dramatically lowering ApoBCL production in these models and also in wild-type mice fed a high fat
diet and in hamsters fed a high carbohydrate diet. If these proof-of-concept studies are successful, our inhibitors
might lead companies to develop new drugs to reduce plasma ApoBCLs and prevent coronary heart disease.
血浆中富含甘油三酯的载脂蛋白(apobcl)水平升高是主要的致病因素
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arun Radhakrishnan其他文献
Arun Radhakrishnan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arun Radhakrishnan', 18)}}的其他基金
Targeting Scap to Lower ApoB-Containing Lipoproteins (ApoBCL) Production
靶向 Scap 降低含 ApoB 脂蛋白 (ApoBCL) 的产生
- 批准号:
10332596 - 财政年份:2022
- 资助金额:
$ 54.12万 - 项目类别:
相似海外基金
Black Soldier Fly Pilot Trial - Innovative Black Soldier Fly (BSF) Micro Farm (MF) Project, reclaiming waste feed inputs and converting it into proteins for animal feed
黑水虻试点试验 - 创新的黑水虻 (BSF) 微型农场 (MF) 项目,回收废弃饲料投入并将其转化为动物饲料的蛋白质
- 批准号:
10071795 - 财政年份:2023
- 资助金额:
$ 54.12万 - 项目类别:
Collaborative R&D
Decarbonising F&B sectors and animal feed production using engineered biological consortia applying circular principles
脱碳F
- 批准号:
10075214 - 财政年份:2023
- 资助金额:
$ 54.12万 - 项目类别:
Grant for R&D
Mealworm protein for animal feed: Automating and optimising production.
用于动物饲料的黄粉虫蛋白:自动化和优化生产。
- 批准号:
10053146 - 财政年份:2023
- 资助金额:
$ 54.12万 - 项目类别:
Collaborative R&D
Insects for sustainable animal feed: Livestock farming in a climate change challenged world
用于可持续动物饲料的昆虫:气候变化挑战世界中的畜牧业
- 批准号:
2886903 - 财政年份:2023
- 资助金额:
$ 54.12万 - 项目类别:
Studentship
Enhancing seaweed aquaculture for alternative animal feed
加强海藻养殖以替代动物饲料
- 批准号:
2900694 - 财政年份:2023
- 资助金额:
$ 54.12万 - 项目类别:
Studentship
AAFCO Animal Feed Regulatory Program Standards Meeting
AAFCO 动物饲料监管计划标准会议
- 批准号:
10506966 - 财政年份:2022
- 资助金额:
$ 54.12万 - 项目类别:
Black Soldier Fly (BSF) technology recycles food waste into a new source of animal feed (i.e. BSF larvae)
黑水虻 (BSF) 技术将食物垃圾回收为新的动物饲料来源(即 BSF 幼虫)
- 批准号:
2718183 - 财政年份:2022
- 资助金额:
$ 54.12万 - 项目类别:
Studentship
Development and Maintenance of the Animal Feed Regulatory Program Standards
动物饲料监管计划标准的制定和维护
- 批准号:
10662470 - 财政年份:2022
- 资助金额:
$ 54.12万 - 项目类别:
Maintenance of the Animal Feed Regulatory Program Standards with Coordinated Preventive Control Regulatory Activities and Capacity Building in South Carolina
通过协调南卡罗来纳州的预防控制监管活动和能力建设来维持动物饲料监管计划标准
- 批准号:
10662499 - 财政年份:2022
- 资助金额:
$ 54.12万 - 项目类别:
NASDA Foundation and AAAFCO, Long-Term Improvements to the National Animal Food Safety System and Promotion of the Animal Feed Regulatory Program Standards (AFRPS)
NASDA 基金会和 AAAFCO,国家动物食品安全体系的长期改进和动物饲料监管计划标准 (AFRPS) 的推广
- 批准号:
10600706 - 财政年份:2022
- 资助金额:
$ 54.12万 - 项目类别:














{{item.name}}会员




